{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:36:15Z","timestamp":1771583775479,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10067-026-07941-2","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:55:10Z","timestamp":1769064910000},"page":"1637-1650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune thrombocytopenia in\u00a0patients with\u00a0connective tissue disease"],"prefix":"10.1007","volume":"45","author":[{"given":"Kai","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilv","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6521-5159","authenticated-orcid":false,"given":"Taoyuan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"11","key":"7941_CR1","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"issue":"4","key":"7941_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042163","volume":"25","author":"A Mititelu","year":"2024","unstructured":"Mititelu A, Onis\u00e2i M-C, Ro\u0219ca A, Vl\u0103d\u0103reanu AM (2024) Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options. Int J Mol Sci 25(4):2163. https:\/\/doi.org\/10.3390\/ijms25042163","journal-title":"Int J Mol Sci"},{"key":"7941_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101112","volume":"61","author":"TJ Gonzalez-Lopez","year":"2023","unstructured":"Gonzalez-Lopez TJ, Provan D, Barez A, Bernardo-Guti\u00e9rrez A, Bernat S, Martinez-Carballeira D et al (2023) Primary and secondary immune thrombocytopenia (ITP): time for a rethink. Blood Rev 61:101112. https:\/\/doi.org\/10.1016\/j.blre.2023.101112","journal-title":"Blood Rev"},{"issue":"2","key":"7941_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae029","volume":"8","author":"X Jiang","year":"2024","unstructured":"Jiang X, Shu X, Ge Y (2024) Effectiveness and safety of eltrombopag in connective tissue disease patients with refractory immune thrombocytopenia: a retrospective study. Rheumatol Adv Pract 8(2):rkae029. https:\/\/doi.org\/10.1093\/rap\/rkae029","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"7941_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/annrheumdis-2020-217356","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Bertsias G, Boumpas DT (2020) Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or \u2018blood-dominant\u2019 lupus? Ann Rheum Dis 79(6):683\u2013684. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217356","journal-title":"Ann Rheum Dis"},{"issue":"50","key":"7941_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005565","volume":"95","author":"Y Liu","year":"2016","unstructured":"Liu Y, Chen S, Sun Y, Lin Q, Liao X, Zhang J et al (2016) Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study. Medicine (Baltimore) 95(50):e5565. https:\/\/doi.org\/10.1097\/MD.0000000000005565","journal-title":"Medicine (Baltimore)"},{"issue":"1 Suppl 2","key":"7941_CR7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","volume":"46","author":"DB Cines","year":"2009","unstructured":"Cines DB, Liebman H, Stasi R (2009) Pathobiology of secondary immune thrombocytopenia. Semin Hematol 46(1 Suppl 2):S2\u2013S14. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.12.005","journal-title":"Semin Hematol"},{"issue":"4","key":"7941_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11926-011-0179-5","volume":"13","author":"AB Levine","year":"2011","unstructured":"Levine AB, Erkan D (2011) Clinical assessment and management of cytopenias in lupus patients. Curr Rheumatol Rep 13(4):291\u2013299. https:\/\/doi.org\/10.1007\/s11926-011-0179-5","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"7941_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.22376","volume":"56","author":"M Fern\u00e1ndez","year":"2007","unstructured":"Fern\u00e1ndez M, Alarc\u00f3n GS, Apte M, Andrade RM, Vil\u00e1 LM, Reveille JD (2007) Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 56(2):614\u2013621. https:\/\/doi.org\/10.1002\/art.22376","journal-title":"Arthritis Rheum"},{"issue":"6","key":"7941_CR10","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2017.10.003","volume":"140","author":"NR Jog","year":"2017","unstructured":"Jog NR, James JA (2017) Biomarkers in connective tissue diseases. J Allergy Clin Immunol 140(6):1473\u20131483. https:\/\/doi.org\/10.1016\/j.jaci.2017.10.003","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"7941_CR11","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10067-020-05152-x","volume":"39","author":"F Sun","year":"2020","unstructured":"Sun F, Chen J, Wu W, Geng S, Xu W, Sun S et al (2020) Rituximab or cyclosporin in refractory immune thrombocytopenia secondary to connective tissue diseases: a real-world observational retrospective study. Clin Rheumatol 39(10):3099\u20133104. https:\/\/doi.org\/10.1007\/s10067-020-05152-x","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7941_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"7941_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejim.2022.11.022","volume":"108","author":"A Gafter-Gvili","year":"2023","unstructured":"Gafter-Gvili A (2023) Current approaches for the diagnosis and management of immune thrombocytopenia. Eur J Intern Med 108:18\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2022.11.022","journal-title":"Eur J Intern Med"},{"issue":"8","key":"7941_CR14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/j.1538-7836.2005.01376.x","volume":"3","author":"BH Chong","year":"2005","unstructured":"Chong BH, Ho SJ (2005) Autoimmune thrombocytopenia. J Thromb Haemost 3(8):1763\u20131772. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01376.x","journal-title":"J Thromb Haemost"},{"issue":"12","key":"7941_CR15","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1007\/s10067-018-4312-y","volume":"37","author":"W Zhang","year":"2018","unstructured":"Zhang W, Wang F, Wang H, Hua B, Feng X, Sun L (2018) Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases. Clin Rheumatol 37(12):3337\u20133344. https:\/\/doi.org\/10.1007\/s10067-018-4312-y","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7941_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2547455","volume":"30","author":"Y Sun","year":"2025","unstructured":"Sun Y, Yang J, Li L, Song J, Dong X, Fu R, Wang H (2025) Comparative analysis of primary immune thrombocytopenia and immune thrombocytopenia secondary to connective tissue diseases. Hematology 30(1):2547455. https:\/\/doi.org\/10.1080\/16078454.2025.2547455","journal-title":"Hematology"},{"key":"7941_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102887","volume":"132","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Cheng Y, Ma S, Li T, Chen Z, Zuo X et al (2022) Systemic lupus erythematosus-complicating immune thrombocytopenia: from pathogenesis to treatment. J Autoimmun 132:102887. https:\/\/doi.org\/10.1016\/j.jaut.2022.102887","journal-title":"J Autoimmun"},{"key":"7941_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102615","volume":"119","author":"A Thanou","year":"2021","unstructured":"Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME (2021) Clinical disease activity and flare in SLE: current concepts and novel biomarkers. J Autoimmun 119:102615. https:\/\/doi.org\/10.1016\/j.jaut.2021.102615","journal-title":"J Autoimmun"},{"issue":"9","key":"7941_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey\u2010Goldman R et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheum 71(9):1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheum"},{"issue":"6","key":"7941_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/annrheumdis-2020-217013","volume":"79","author":"F-X Zhu","year":"2020","unstructured":"Zhu F-X, Huang J-Y, Ye Z, Wen Q-Q, Wei JC-C (2020) Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study. Ann Rheum Dis 79(6):793\u2013799. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7941_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000523","volume":"8","author":"Y Liu","year":"2021","unstructured":"Liu Y, Chen S, Yang G, Wang B, Lan J, Dai F et al (2021) ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases. Lupus Sci Med 8(1):e000523. https:\/\/doi.org\/10.1136\/lupus-2021-000523","journal-title":"Lupus Sci Med"},{"issue":"9","key":"7941_CR22","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/rheumatology\/keab925","volume":"61","author":"M Roussotte","year":"2022","unstructured":"Roussotte M, Gerfaud-Valentin M, Hot A, Audia S, Bonnotte B, Thibault T et al (2022) Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients. Rheumatology (Oxford) 61(9):3627\u20133639. https:\/\/doi.org\/10.1093\/rheumatology\/keab925","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"7941_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.medcli.2023.12.012","volume":"162","author":"JC Lema","year":"2024","unstructured":"Lema JC, S\u00e1nchez-Gonz\u00e1lez B, Carri\u00f3n-Barber\u00e0 I, de Oca SVM, Pallarols FG, Salman-Monte TC (2024) Immune thrombocytopenia in systemic lupus erythematosus: prevalence, risk factors, and a novel predictive model for risk assessment. Med Clin (Barc) 162(10):461\u2013469. https:\/\/doi.org\/10.1016\/j.medcli.2023.12.012","journal-title":"Med Clin (Barc)"},{"key":"7941_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00202-7","volume":"61","author":"X Zeng","year":"2021","unstructured":"Zeng X, Zheng L, Rui H, Kang R, Chen J, Chen H et al (2021) Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis. Adv Rheumatol 61:43. https:\/\/doi.org\/10.1186\/s42358-021-00202-7","journal-title":"Adv Rheumatol"},{"issue":"2","key":"7941_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.survophthal.2019.10.004","volume":"65","author":"O Bjordal","year":"2020","unstructured":"Bjordal O, Norheim KB, R\u00f8dahl E, Jonsson R, Omdal R (2020) Primary Sj\u00f6gren\u2019s syndrome and the eye. Surv Ophthalmol 65(2):119\u2013132. https:\/\/doi.org\/10.1016\/j.survophthal.2019.10.004","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"7941_CR26","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-162","volume":"10","author":"J Wu","year":"2022","unstructured":"Wu J, Chang X, Zhang J, Liu C, Liu M, Chen W (2022) Clinical and laboratory features of primary Sj\u00f6gren\u2019s syndrome complicated with mild to severe thrombocytopenia. Ann Transl Med 10(6):300. https:\/\/doi.org\/10.21037\/atm-22-162","journal-title":"Ann Transl Med"},{"key":"7941_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00138","volume":"7","author":"F Dai","year":"2020","unstructured":"Dai F, Yang G, Rao P, Wu P, Chen R, Sun Y et al (2020) Clinical characteristics of secondary immune thrombocytopenia associated with primary Sj\u00f6gren\u2019s syndrome. Front Med (Lausanne) 7:138. https:\/\/doi.org\/10.3389\/fmed.2020.00138","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"7941_CR28","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.55563\/clinexprheumatol\/8hgmjm","volume":"40","author":"J Luo","year":"2022","unstructured":"Luo J, Song W-J, Chen J-Q, Yang G-Y, Yang J-Y, Yu X-B et al (2022) Factors associated with secondary immune thrombocytopenia in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective study of 639 cases. Clin Exp Rheumatol 40(12):2245\u20132252. https:\/\/doi.org\/10.55563\/clinexprheumatol\/8hgmjm","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"7941_CR29","doi-asserted-by":"publisher","DOI":"10.4038\/jpgim.8294","volume":"7","author":"S Rupasinghe","year":"2020","unstructured":"Rupasinghe S, Kularatne W (2020) Mixed connective tissue disease with secondary immune thrombocytopenic purpura\u2013a case report. J Postgrad Inst Med Educ Res 7(2):e179. https:\/\/doi.org\/10.4038\/jpgim.8294","journal-title":"J Postgrad Inst Med Educ Res"},{"issue":"2","key":"7941_CR30","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1093\/rheumatology\/keab732","volume":"61","author":"Y Oto","year":"2022","unstructured":"Oto Y, Shimoyama T, Ukichi T, Yoshida K, Kurosaka D (2022) Secondary immune thrombocytopenia with elevated serum ferritin in a patient with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 61(2):e40\u2013e42. https:\/\/doi.org\/10.1093\/rheumatology\/keab732","journal-title":"Rheumatology"},{"issue":"4","key":"7941_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105560","volume":"90","author":"G Boleto","year":"2023","unstructured":"Boleto G, Avouac J, Godeau B, Allanore Y (2023) Severe immune thrombocytopenia in two patients with systemic sclerosis. Joint Bone Spine 90(4):105560. https:\/\/doi.org\/10.1016\/j.jbspin.2023.105560","journal-title":"Joint Bone Spine"},{"issue":"1","key":"7941_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01401-z","volume":"16","author":"X-g Liu","year":"2023","unstructured":"Liu X-g, Hou Y, Hou M (2023) How we treat primary immune thrombocytopenia in adults. J Hematol Oncol 16(1):4. https:\/\/doi.org\/10.1186\/s13045-023-01401-z","journal-title":"J Hematol Oncol"},{"issue":"7","key":"7941_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070779","volume":"15","author":"ME Mingot-Castellano","year":"2022","unstructured":"Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, Entrena Ure\u00f1a L, Gonz\u00e1lez-L\u00f3pez TJ, Gonz\u00e1lez-Porras JR et al (2022) Novel therapies to address unmet needs in ITP. Pharmaceuticals (Basel) 15(7):779. https:\/\/doi.org\/10.3390\/ph15070779","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"7941_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3324\/haematol.2019.240440","volume":"106","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen W, Zhang W, Lee-Sundlov MM, Casari C, Berndt MC et al (2020) Desialylation of O-glycans on glycoprotein Ib\u03b1 drives receptor signaling and platelet clearance. Haematologica 106(1):220\u2013229. https:\/\/doi.org\/10.3324\/haematol.2019.240440","journal-title":"Haematologica"},{"issue":"1","key":"7941_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","volume":"4","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Rosovsky RP, Karp Leaf RS, Smith DB, Goodarzi K, Fogerty AE et al (2020) A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv 4(1):9\u201318. https:\/\/doi.org\/10.1182\/bloodadvances.2019000868","journal-title":"Blood Adv"},{"issue":"1","key":"7941_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3324\/haematol.2020.248385","volume":"106","author":"PA Norris","year":"2020","unstructured":"Norris PA, Segel GB, Burack WR, Sachs UJ, Lissenberg-Thunnissen SN, Vidarsson G et al (2020) Fc\u03b3RI and Fc\u03b3RIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia. Haematologica 106(1):250\u2013254. https:\/\/doi.org\/10.3324\/haematol.2020.248385","journal-title":"Haematologica"},{"key":"7941_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1215216","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Murakhovskaya I (2023) Rituximab resistance in ITP and beyond. Front Immunol 14:1215216. https:\/\/doi.org\/10.3389\/fimmu.2023.1215216","journal-title":"Front Immunol"},{"issue":"1","key":"7941_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nm.3770","volume":"21","author":"R Grozovsky","year":"2015","unstructured":"Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H et al (2015) The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 21(1):47\u201354. https:\/\/doi.org\/10.1038\/nm.3770","journal-title":"Nat Med"},{"issue":"31","key":"7941_CR39","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1073\/pnas.1707662114","volume":"114","author":"Y Li","year":"2017","unstructured":"Li Y, Fu J, Ling Y, Yago T, McDaniel JM, Song J et al (2017) Sialylation on O-glycans protects platelets from clearance by liver Kupffer cells. Proc Natl Acad Sci U S A 114(31):8360\u20138365. https:\/\/doi.org\/10.1073\/pnas.1707662114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7941_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000078","volume":"2","author":"A Fayyaz","year":"2015","unstructured":"Fayyaz A, Igoe A, Kurien BT, Danda D, James JA, Stafford HA et al (2015) Haematological manifestations of lupus. Lupus Sci Med 2(1):e000078. https:\/\/doi.org\/10.1136\/lupus-2014-000078","journal-title":"Lupus Sci Med"},{"issue":"6","key":"7941_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.autrev.2018.01.012","volume":"17","author":"M Scherlinger","year":"2018","unstructured":"Scherlinger M, Guillotin V, Truchetet M-E, Contin-Bordes C, Sisirak V, Duffau P et al (2018) Systemic lupus erythematosus and systemic sclerosis: all roads lead to platelets. Autoimmun Rev 17(6):625\u2013635. https:\/\/doi.org\/10.1016\/j.autrev.2018.01.012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"7941_CR42","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.3390\/cells10123386","volume":"10","author":"S Sun","year":"2021","unstructured":"Sun S, Urbanus RT, Ten Cate H, de Groot PG, de Laat B, Heemskerk JW et al (2021) Platelet activation mechanisms and consequences of immune thrombocytopenia. Cells 10(12):3386. https:\/\/doi.org\/10.3390\/cells10123386","journal-title":"Cells"},{"issue":"7","key":"7941_CR43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","volume":"45","author":"M Kuwana","year":"2006","unstructured":"Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y (2006) Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 45(7):851\u2013854. https:\/\/doi.org\/10.1093\/rheumatology\/kel010","journal-title":"Rheumatology (Oxford)"},{"key":"7941_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1473190","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Fu Y, Yin H, Zhu H (2025) Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review. Front Immunol 16:1473190. https:\/\/doi.org\/10.3389\/fimmu.2025.1473190","journal-title":"Front Immunol"},{"key":"7941_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clim.2017.12.010","volume":"188","author":"J Kamhieh-Milz","year":"2018","unstructured":"Kamhieh-Milz J, Ghosoun N, Sterzer V, Salama A (2018) Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP). Clin Immunol 188:74\u201380. https:\/\/doi.org\/10.1016\/j.clim.2017.12.010","journal-title":"Clin Immunol"},{"key":"7941_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00885","volume":"10","author":"SL Savelli","year":"2019","unstructured":"Savelli SL, Roubey RA, Kitzmiller KJ, Zhou D, Nagaraja HN, Mulvihill E et al (2019) Opposite profiles of complement in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) among patients with antiphospholipid antibodies (aPL). Front Immunol 10:885. https:\/\/doi.org\/10.3389\/fimmu.2019.00885","journal-title":"Front Immunol"},{"issue":"D1","key":"7941_CR47","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T et al (2025) Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 53(D1):D1670\u2013D1676. https:\/\/doi.org\/10.1093\/nar\/gkae973","journal-title":"Nucleic Acids Res"},{"key":"7941_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110716","volume":"123","author":"F Sun","year":"2023","unstructured":"Sun F, Tang Q, Cheng W, Xie X, Li F, Chen J (2023) Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome. Int Immunopharmacol 123:110716. https:\/\/doi.org\/10.1016\/j.intimp.2023.110716","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"7941_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne G, Mariette X (2018) B cells in the pathogenesis of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 14(3):133\u2013145. https:\/\/doi.org\/10.1038\/nrrheum.2018.1","journal-title":"Nat Rev Rheumatol"},{"key":"7941_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637659","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Qu J, Wang L, Li M, Xu D, Zhao Y et al (2021) Activation of toll-like receptor 7 signaling pathway in primary Sj\u00f6gren\u2019s syndrome-associated thrombocytopenia. Front Immunol 12:637659. https:\/\/doi.org\/10.3389\/fimmu.2021.637659","journal-title":"Front Immunol"},{"issue":"1","key":"7941_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10067-023-06818-y","volume":"43","author":"Y Ruan","year":"2024","unstructured":"Ruan Y, Bi H, Luo X, Pang A, Zhang P, Cui Y (2024) Elevated plasma levels of specific antiplatelet glycoprotein autoantibodies in patients with primary Sj\u00f6gren syndrome with thrombocytopenia. Clin Rheumatol 43(1):307\u2013314. https:\/\/doi.org\/10.1007\/s10067-023-06818-y","journal-title":"Clin Rheumatol"},{"key":"7941_CR52","doi-asserted-by":"publisher","unstructured":"Xu R, Yan Q, Gong Y, Cai C-S, Wu J, Yuan X-Y et al (2022) Tacrolimus therapy in primary Sj\u00f6gren\u2019s syndrome with refractory immune thrombocytopenia: a retrospective study. Clin Exp Rheumatol 40(12):2268\u20132274.\u00a0https:\/\/doi.org\/10.55563\/clinexprheumatol\/5c7l01","DOI":"10.55563\/clinexprheumatol\/5c7l01"},{"key":"7941_CR53","doi-asserted-by":"publisher","unstructured":"Hu Y-H, Zhou P-F, Long G-F, Tian X, Guo Y-F, Pang A-M et al (2015) Elevated plasma P-selectin autoantibodies in primary Sj\u00f6gren syndrome patients with thrombocytopenia. Med Sci Monit 21:3690\u20133696.\u00a0https:\/\/doi.org\/10.12659\/msm.895144","DOI":"10.12659\/msm.895144"},{"issue":"12","key":"7941_CR54","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.55563\/clinexprheumatol\/cmmkod","volume":"42","author":"Y Song","year":"2024","unstructured":"Song Y, Zhou W (2024) Role of TLR7 in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 42(12):2513\u20132519. https:\/\/doi.org\/10.55563\/clinexprheumatol\/cmmkod","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7941_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13410","volume":"329","author":"S Gupta","year":"2025","unstructured":"Gupta S, Cassel SL, Sutterwala FS, Dagvadorj J (2025) Regulation of the NLRP3 inflammasome by autophagy and mitophagy. Immunol Rev 329(1):e13410. https:\/\/doi.org\/10.1111\/imr.13410","journal-title":"Immunol Rev"},{"issue":"2","key":"7941_CR56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ajh.23609","volume":"89","author":"M Khellaf","year":"2014","unstructured":"Khellaf M, Chabrol A, Mahevas M, Roudot-Thoraval F, Limal N, Languille L, Bierling P, Michel M, Godeau B (2014) Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol 89(2):194\u2013198. https:\/\/doi.org\/10.1002\/ajh.23609","journal-title":"Am J Hematol"},{"issue":"5","key":"7941_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30911","volume":"71","author":"D Brik-Simon","year":"2024","unstructured":"Brik-Simon D, Efros O, Levinsky Y, Amarilyo G, Tirosh I, Levy-Mendelovich S, Steinberg-Shemer O, Izraeli S, Yacobovich J, Gilad O (2024) Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia. Pediatr Blood Cancer 71(5):e30911. https:\/\/doi.org\/10.1002\/pbc.30911","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"7941_CR58","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s10067-024-07031-1","volume":"43","author":"E Cim\u00e9-Ak\u00e9","year":"2024","unstructured":"Cim\u00e9-Ak\u00e9 E, Barrera-Vargas A, Demichelis-G\u00f3mez R, Ram\u00edrez-Alem\u00f3n M, Rull-Gabayet M (2024) Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse. Clin Rheumatol 43(8):2521\u20132532. https:\/\/doi.org\/10.1007\/s10067-024-07031-1","journal-title":"Clin Rheumatol"},{"issue":"6","key":"7941_CR59","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/09612033241241576","volume":"33","author":"Q Wu","year":"2024","unstructured":"Wu Q, Zhao MX, Huang XS, Lin CS, Xu Q (2024) The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: a retrospective cohort study. Lupus 33(6):608\u2013614. https:\/\/doi.org\/10.1177\/09612033241241576","journal-title":"Lupus"},{"issue":"1","key":"7941_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001501","volume":"12","author":"X Yuan","year":"2025","unstructured":"Yuan X, Li T, Liu Y, Wang M, Zuo X, Jiang Y, Zhang X (2025) Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease. Lupus Sci Med 12(1):e001224. https:\/\/doi.org\/10.1136\/lupus-2025-001501","journal-title":"Lupus Sci Med"},{"issue":"3","key":"7941_CR61","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3748\/wjg.v20.i3.714","volume":"20","author":"M Kuwana","year":"2014","unstructured":"Kuwana M (2014) Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol 20(3):714\u2013723. https:\/\/doi.org\/10.3748\/wjg.v20.i3.714","journal-title":"World J Gastroenterol"},{"issue":"7","key":"7941_CR62","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.2019003599","volume":"135","author":"O Miltiadous","year":"2020","unstructured":"Miltiadous O, Hou M, Bussel JB (2020) Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 135(7):472\u2013490. https:\/\/doi.org\/10.1182\/blood.2019003599","journal-title":"Blood"},{"issue":"22","key":"7941_CR63","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","journal-title":"Blood Adv"},{"issue":"6","key":"7941_CR64","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3899\/jrheum.150829","volume":"43","author":"L Zhao","year":"2016","unstructured":"Zhao L, Xu D, Qiao L, Zhang X (2016) Bone marrow megakaryocytes may predict therapeutic response of severe thrombocytopenia in patients with systemic lupus erythematosus. J Rheumatol 43(6):1038\u20131044. https:\/\/doi.org\/10.3899\/jrheum.150829","journal-title":"J Rheumatol"},{"issue":"7","key":"7941_CR65","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/1756-185X.14707","volume":"26","author":"H Zhong","year":"2023","unstructured":"Zhong H, Xue Y, Zhang L, Yang Y, Zhou J, Zhang S et al (2023) Predictive value of bone marrow megakaryocyte count for immunotherapeutic response in primary Sj\u00f6gren\u2019s syndrome patients with severe immune thrombocytopenia: a single\u2010center case\u2013control study in China. Int J Rheum Dis 26(7):1260\u20131267. https:\/\/doi.org\/10.1111\/1756-185X.14707","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"7941_CR66","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/1756-185X.14811","volume":"26","author":"Y Fu","year":"2023","unstructured":"Fu Y, Zhao L, Ye S (2023) Intention to treat: the management of connective tissue disease-related immune thrombocytopenia. Int J Rheum Dis 26(10):1853\u20131864. https:\/\/doi.org\/10.1111\/1756-185X.14811","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"7941_CR67","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","volume":"21","author":"Y-H Qin","year":"2010","unstructured":"Qin Y-H, Zhou T-B, Su L-N, Lei F-Y, Zhao Y-J, Huang W-F (2010) The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis 21(8):713\u2013721. https:\/\/doi.org\/10.1097\/MBC.0b013e3283401490","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"7941_CR68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ejh.13319","volume":"103","author":"M Witkowski","year":"2019","unstructured":"Witkowski M, Witkowska M, Robak T (2019) Autoimmune thrombocytopenia: current treatment options in adults with a focus on novel drugs. Eur J Haematol 103(6):531\u2013541. https:\/\/doi.org\/10.1111\/ejh.13319","journal-title":"Eur J Haematol"},{"issue":"23","key":"7941_CR69","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"issue":"24","key":"7941_CR70","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/bloodadvances.2017009860","volume":"1","author":"CE Neunert","year":"2017","unstructured":"Neunert CE (2017) Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv 1(24):2295\u20132301. https:\/\/doi.org\/10.1182\/bloodadvances.2017009860","journal-title":"Blood Adv"},{"key":"7941_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100811","volume":"49","author":"DJ Kuter","year":"2021","unstructured":"Kuter DJ, Tarantino MD, Lawrence T (2021) Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Rev 49:100811. https:\/\/doi.org\/10.1016\/j.blre.2021.100811","journal-title":"Blood Rev"},{"key":"7941_CR72","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/DDDT.S299591","volume":"15","author":"JB Bussel","year":"2021","unstructured":"Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW (2021) A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther 15:2243\u20132268. https:\/\/doi.org\/10.2147\/DDDT.S299591","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"7941_CR73","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","volume":"113","author":"JB Bussel","year":"2009","unstructured":"Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113(10):2161\u20132171. https:\/\/doi.org\/10.1182\/blood-2008-04-150078","journal-title":"Blood"},{"issue":"5","key":"7941_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100192","volume":"7","author":"H Zhou","year":"2023","unstructured":"Zhou H, Zhou J, Wu D, Ma L, Du X, Niu T et al (2023) Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China. Res Pract Thromb Haemost 7(5):100192. https:\/\/doi.org\/10.1016\/j.rpth.2023.100192","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"7941_CR75","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3899\/jrheum.140080","volume":"41","author":"L Magnano","year":"2014","unstructured":"Magnano L, Enriquez H, Esteve J, Cervera R, Espinosa G (2014) Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. J Rheumatol 41(9):1895\u20131896. https:\/\/doi.org\/10.3899\/jrheum.140080","journal-title":"J Rheumatol"},{"issue":"1","key":"7941_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-024-03472-w","volume":"27","author":"S Deng","year":"2025","unstructured":"Deng S, Wang B, Hu Z, Cai S, Dong L (2025) Eltrombopag for the treatment of refractory connective tissue disease-related thrombocytopenia: a pilot study of 52 cases. Arthritis Res Ther 27(1):7. https:\/\/doi.org\/10.1186\/s13075-024-03472-w","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"7941_CR77","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1038\/s41598-021-84493-2","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Dai M, Fu Q, Chen S (2021) Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease. Sci Rep 11(1):5459. https:\/\/doi.org\/10.1038\/s41598-021-84493-2","journal-title":"Sci Rep"},{"issue":"2","key":"7941_CR78","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ajh.27080","volume":"99","author":"ZM Virk","year":"2024","unstructured":"Virk ZM, Leaf RK, Kuter DJ, Goodarzi K, Connell NT, Connors JM et al (2024) Avatrombopag for adults with early versus chronic immune thrombocytopenia. Am J Hematol 99(2):155\u2013162. https:\/\/doi.org\/10.1002\/ajh.27080","journal-title":"Am J Hematol"},{"issue":"12","key":"7941_CR79","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/ajh.27498","volume":"99","author":"C Pascual-Izquierdo","year":"2024","unstructured":"Pascual-Izquierdo C, S\u00e1nchez-Gonz\u00e1lez B, Canaro-Hirnyk MI, Garc\u00eda-Donas G, Menor-G\u00f3mez M, Gil-Fern\u00e1ndez JJ et al (2024) Avatrombopag in immune thrombocytopenia: a real-world study of the Spanish ITP group (GEPTI). Am J Hematol 99(12):2328\u20132339. https:\/\/doi.org\/10.1002\/ajh.27498","journal-title":"Am J Hematol"},{"issue":"12","key":"7941_CR80","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1093\/rheumatology\/keq269","volume":"49","author":"AL Hepburn","year":"2010","unstructured":"Hepburn AL, Narat S, Mason JC (2010) The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 49(12):2243\u20132254. https:\/\/doi.org\/10.1093\/rheumatology\/keq269","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"7941_CR81","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","volume":"21","author":"B Jiang","year":"2015","unstructured":"Jiang B, Li T, Guo L, Shen H, Ye S, Chen S (2015) Efficacy and safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol 21(5):244\u2013250. https:\/\/doi.org\/10.1097\/RHU.0000000000000273","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"7941_CR82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ajh.24999","volume":"93","author":"A Serris","year":"2018","unstructured":"Serris A, Amoura Z, Canou\u00ef-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N et al (2018) Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 93(3):424\u2013429. https:\/\/doi.org\/10.1002\/ajh.24999","journal-title":"Am J Hematol"},{"issue":"3","key":"7941_CR83","doi-asserted-by":"publisher","first-page":"476","DOI":"10.46497\/ArchRheumatol.2024.10564","volume":"39","author":"DB G\u00f6kten","year":"2024","unstructured":"G\u00f6kten DB, Kavak FY, Mercan R (2024) Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus? Arch Rheumatol 39(3):476\u2013483. https:\/\/doi.org\/10.46497\/ArchRheumatol.2024.10564","journal-title":"Arch Rheumatol"},{"issue":"7","key":"7941_CR84","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Treli\u0144ski J, Homenda W et al (2018) Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo\u2010controlled trials. Am J Hematol 93(7):921\u2013930. https:\/\/doi.org\/10.1002\/ajh.25125","journal-title":"Am J Hematol"},{"issue":"1","key":"7941_CR85","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2022.2131751","volume":"34","author":"N Cooper","year":"2023","unstructured":"Cooper N, Ghanima W, Hill QA, Nicolson PL, Markovtsov V, Kessler C (2023) Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets 34(1):2131751. https:\/\/doi.org\/10.1080\/09537104.2022.2131751","journal-title":"Platelets"},{"issue":"6","key":"7941_CR86","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2024024250","volume":"144","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2024","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Bermejo-Vega N, Cardesa-Cabrera R, Mart\u00ednez-Robles V, Aguilar-Monserrate G, P\u00e9rez-Segura G et al (2024) Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood 144(6):646\u2013656. https:\/\/doi.org\/10.1182\/blood.2024024250","journal-title":"Blood"},{"issue":"5","key":"7941_CR87","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.25444","volume":"94","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H et al (2019) Long\u2010term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol 94(5):546\u2013553. https:\/\/doi.org\/10.1002\/ajh.25444","journal-title":"Am J Hematol"},{"key":"7941_CR88","doi-asserted-by":"publisher","DOI":"10.1155\/mi\/5578929","volume":"2025","author":"A Heidari","year":"2025","unstructured":"Heidari A, Mazid AS, Behroozfar M, Ghotbi N, Fathabadi F, Eghbali S et al (2025) Efficacy and safety of Syk and BTK inhibitors in immune thrombocytopenia: a comprehensive review of emerging evidence. Mediators Inflamm 2025:5578929. https:\/\/doi.org\/10.1155\/mi\/5578929","journal-title":"Mediators Inflamm"},{"key":"7941_CR89","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211010875","volume":"12","author":"N Cooper","year":"2021","unstructured":"Cooper N, Altomare I, Thomas MR, Nicolson PL, Watson SP, Markovtsov V et al (2021) Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol 12:20406207211010875. https:\/\/doi.org\/10.1177\/20406207211010875","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"7941_CR90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jox13010005","volume":"13","author":"MA Ali","year":"2023","unstructured":"Ali MA, Anwar MY, Aiman W, Dhanesar G, Omar Z, Hamza M et al (2023) Safety and efficacy of tyrosine kinase inhibitors in immune thrombocytopenic purpura: a systematic review of clinical trials. J Xenobiot 13(1):29\u201341. https:\/\/doi.org\/10.3390\/jox13010005","journal-title":"J Xenobiot"},{"key":"7941_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953716","volume":"13","author":"Y Lv","year":"2022","unstructured":"Lv Y, Shi H, Liu H, Zhou L (2022) Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently? Front Immunol 13:953716. https:\/\/doi.org\/10.3389\/fimmu.2022.953716","journal-title":"Front Immunol"},{"issue":"2","key":"7941_CR92","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, S\u00e1nchez\u2010Gonz\u00e1lez B, Rejt\u0151 L, Egyed M, Romanyuk N, Godar M et al (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95(2):178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680","journal-title":"Am J Hematol"},{"issue":"17","key":"7941_CR93","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","volume":"4","author":"T Robak","year":"2020","unstructured":"Robak T, Ka\u017amierczak M, Jarque I, Musteata V, Treli\u0144ski J, Cooper N et al (2020) Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv 4(17):4136\u20134146. https:\/\/doi.org\/10.1182\/bloodadvances.2020002003","journal-title":"Blood Adv"},{"issue":"1","key":"7941_CR94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/rheumatology\/kead160","volume":"63","author":"H Du","year":"2024","unstructured":"Du H, Su W, Su J, Hu J, Wu D, Long W et al (2024) Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study. Rheumatology (Oxford) 63(1):79\u201384. https:\/\/doi.org\/10.1093\/rheumatology\/kead160","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07941-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:24Z","timestamp":1771581204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07941-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7941"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07941-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}